Bollinger Band Squeeze Stocks
AQST appears in our Bollinger Band Squeeze Stocks screen. This means the stock is showing a tight volatility setup, where the Bollinger Bands have narrowed and price may be preparing for a larger breakout move.
AQUESTIVE THERAPEUTICS INC (AQST) Stock Price & Overview
NASDAQ:AQST • US03843E1047
Current stock price
4.32 USD
+0.06 (+1.41%)
At close:
4.3 USD
-0.02 (-0.46%)
After Hours:
The current stock price of AQST is 4.32 USD. Today AQST is up by 1.41%. In the past month the price increased by 6.4%. In the past year, price increased by 72.11%.
AQST Key Statistics
52-Week Range2.12 - 7.55
Current AQST stock price positioned within its 52-week range.
1-Month Range3.7664 - 4.4
Current AQST stock price positioned within its 1-month range.
- Market Cap
- 527.256M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.67
- Dividend Yield
- N/A
AQST Stock Performance
Today
+1.41%
1 Week
+5.88%
1 Month
+6.40%
3 Months
+30.51%
Longer-term
6 Months -38.98%
1 Year +72.11%
2 Years +28.57%
3 Years +222.39%
5 Years +6.14%
10 Years N/A
AQST Stock Chart
AQST Stock Screens
AQST currently appears in the following ChartMill screener lists.
AQST Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to AQST. When comparing the yearly performance of all stocks, AQST is one of the better performing stocks in the market, outperforming 88.84% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
AQST Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AQST. Both the profitability and financial health of AQST have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AQST Earnings
On March 4, 2026 AQST reported an EPS of -0.15 and a revenue of 13.02M. The company missed EPS expectations (-10.99% surprise) and missed revenue expectations (-3.95% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateMar 4, 2026
PeriodQ4 / 2025
EPS Reported-$0.15
Revenue Reported13.015M
EPS Surprise -10.99%
Revenue Surprise -3.95%
AQST Forecast & Estimates
15 analysts have analysed AQST and the average price target is 9.07 USD. This implies a price increase of 109.88% is expected in the next year compared to the current price of 4.32.
For the next year, analysts expect an EPS growth of 27.36% and a revenue growth 7.28% for AQST
Analysts
Analysts84
Price Target9.07 (109.95%)
EPS Next Y27.36%
Revenue Next Year7.28%
AQST Groups
Sector & Classification
AQST Financial Highlights
Over the last trailing twelve months AQST reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS decreased by -28.85% compared to the year before.
Income Statements
Revenue(TTM)44.55M
Net Income(TTM)-83.78M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.23% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%21.05%
Sales Q2Q%20.93%
EPS 1Y (TTM)-28.85%
Revenue 1Y (TTM)-22.61%
AQST Ownership
Ownership
Inst Owners61.44%
Shares122.05M
Float115.94M
Ins Owners3.54%
Short Float %15.14%
Short Ratio5.14
AQST Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.51 | 875.877B | ||
| JNJ | JOHNSON & JOHNSON | 18.46 | 564.048B | ||
| MRK | MERCK & CO. INC. | 23.38 | 294.089B | ||
| PFE | PFIZER INC | 9.22 | 156.771B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.5 | 122.851B | ||
| ZTS | ZOETIS INC | 17.3 | 51.463B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.68 | 28.847B | ||
| VTRS | VIATRIS INC | 5.89 | 17.094B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.51 | 11.825B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.667B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.207B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.076B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.07 | 4.91B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AQST
Company Profile
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 147 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. The company has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The firm also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The firm is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Company Info
IPO: 2018-07-25
AQUESTIVE THERAPEUTICS INC
30 Technology Dr
WARREN NEW JERSEY 07059 US
CEO: Keith J. Kendall
Employees: 147
Phone: 19089411900
AQUESTIVE THERAPEUTICS INC / AQST FAQ
What does AQST do?
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 147 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. The company has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The firm also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The firm is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
What is the current price of AQST stock?
The current stock price of AQST is 4.32 USD. The price increased by 1.41% in the last trading session.
What is the dividend status of AQUESTIVE THERAPEUTICS INC?
AQST does not pay a dividend.
What is the ChartMill technical and fundamental rating of AQST stock?
AQST has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for AQST stock?
AQUESTIVE THERAPEUTICS INC (AQST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.67).
Can you provide the ownership details for AQST stock?
You can find the ownership structure of AQUESTIVE THERAPEUTICS INC (AQST) on the Ownership tab.